Kynmobi

(Apomorphine)

ApprovedSmall molecule

Kynmobi is a small molecule that works as a D2-Like Dopamine Receptor Agonist.[2] It is being used across 8 indications, with its most advanced program in Approved.[1]

Kynmobi is one of 183 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

182

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

Parkinson DiseaseRecruiting

Sexual DysfunctionApproved

Sleep DisorderActive, not recruiting

Progressive Supranuclear PalsyActive, not recruiting

EpilepsyApproved

InfusionActive, not recruiting

Parkinson'sCompleted

Erectile DysfunctionApproved

Active, not recruiting

Parkinson DiseaseApproved

Recruiting

Sexual DysfunctionApproved

Approved

Sleep DisorderApproved

Active, not recruiting

Progressive Supranuclear PalsyPreclinical

Active, not recruiting

EpilepsyApproved

Approved

InfusionPhase 3

Active, not recruiting

Parkinson'sPreclinical

Completed

Competition

Competitive Landscape

91 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Lopid

Pfizer

Approved

1 2

Northera

Lundbeck

Approved

1 3

Medrol

Pfizer

Approved

1 4

Aricept

Eisai

Approved

1 5

Rifadin

Azilect

Neupro

Golytely

Actos

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Parkinson Disease

NCT04957095

Clinical

Trials by Indication[1]

Parkinson's Disease7 trials

Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

Unknown status·RRennes University Hospital·Phase 3·NCT02864004·134 enrolled

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT03391882·113 enrolled

Apomorphine Effects on Pain in Parkinson's Disease

Unknown status·UUniversity of Calgary·Phase 2/3·NCT04879134·40 enrolled

Show 4 more trials

Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).

Terminated·FFondation Ophtalmologique Adolphe de Rothschild·Phase 4·NCT02688465·15 enrolled

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

Withdrawn·OOregon Health and Science University·Phase 2·NCT00758368

Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease

Completed·RRennes University Hospital·Phase 4·NCT04887467·19 enrolled

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Completed·BBritannia Pharmaceuticals Ltd.·Phase 2/3·NCT00346827·36 enrolled

Experimental2 trials

The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain

Completed·RRambam Health Care Campus·Phase 4·NCT02969629·59 enrolled

Apomorphine Effects on Experimental Pain

Completed·RRambam Health Care Campus·Phase 1·NCT01744964·105 enrolled

Hallucinations1 trial

Apomorphine in Parkinson's Disease Patients With Visual Hallucinations

Unknown status·UUniversity Medical Center Groningen·Phase 2·NCT02702076·35 enrolled

Parkinson1 trial

Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals

Completed·RRennes University Hospital·N/A·NCT03693872·43 enrolled

Morphine1 trial

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 2·NCT00437177·50 enrolled

7 more indications

Brain Injury1 trial

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

Suspended·NNeuroHealing Pharmaceuticals Inc.·Phase 2·NCT00761228·76 enrolled

Completed·CClinique Beau Soleil·Phase 4·NCT02940912·45 enrolled

Parkinson's1 trial

Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study

Completed·UUniversity Hospital, Toulouse·N/A·NCT00524914·16 enrolled

Infusion1 trial

Infusion of Apomorphine: Long-term Safety Study

Active, not recruiting· Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.·Phase 3·NCT02339064·99 enrolled

Parkinson disease1 trial

Motor Network Physiology Characterization During Deep Brain Stimulation Surgery

Recruiting·UUniversity of Texas Southwestern Medical Center·Preclinical·NCT04957095·120 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 20, 2004

APOKYN

NDA NDA021264

May 21, 2020

KYNMOBI

NDA NDA210875

Feb 3, 2025

ONAPGO

NDA NDA214056

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Apomorphine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apomorphine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Apomorphine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA214056). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Kynmobi. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Samson Clinical Operations Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: D2-Like Dopamine Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSamson Clinical Operations Pty Ltd

Patent Landscape[5]

Patent Cliff

Aug 7, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10821074Aug 7, 2029

9669021Jun 11, 2030

9669019Jun 11, 2030

10420763Jun 11, 2030

9283219Jun 11, 2030

7 more patents

9326981Jun 11, 2030

9044475Jun 11, 2030

8414922Dec 16, 2031

8846074Dec 16, 2031

11419769Dec 16, 2031

10449146Apr 19, 2036

10959943Apr 19, 2036

Kynmobi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Parkinson's Disease7 trials

Experimental2 trials

Hallucinations1 trial

Parkinson1 trial

Morphine1 trial

Brain Injury1 trial

Parkinsonism1 trial

Progressive Supranuclear Palsy1 trial

Sleep Disorder1 trial

Parkinson's1 trial

Infusion1 trial

Parkinson disease1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News